Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CTSH
Jim Cramer Advises His Viewers on HSBC, TJX Companies And More
Earnings Scheduled For November 1, 2017
Cognizant Technology Solutions Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Related ATRA
6 Biotech Stocks Jefferies Says Are Undervalued
10 Biggest Mid-Day Gainers For Tuesday
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold (Seeking Alpha)

 

  • Goldman Sachs downgraded Cognizant Technology Solutions Corp (NASDAQ: CTSH) from Buy to Neutral. The price target for Cognizant Technology has been lowered from $68 to $61. Cognizant Technology shares fell 1.35 percent to $53.30 in pre-market trading.
  • Analysts at Stifel Nicolaus downgraded AMC Networks Inc (NASDAQ: AMCX) from Buy to Hold. AMC Networks shares fell 1.10 percent to $51.40 in pre-market trading.
  • Gabelli & Co. downgraded Penske Automotive Group, Inc. (NYSE: PAG) from Buy to Hold. Penske Automotive shares rose 0.53 percent to close at $49.40 on Wednesday.
  • Analysts at Bank of America downgraded VF Corp (NYSE: VFC) from Buy to Underperform. VF Corp shares dropped 3.08 percent to $56.25 in pre-market trading.
  • CLSA downgraded Monsanto Company (NYSE: MON) from Buy to Underperform. Monsanto shares dropped 0.08 percent to $106.67 in pre-market trading.
  • Analysts at Credit Suisse downgraded Apigee Corp (NASDAQ: APIC) from Outperform to Neutral. Apigee shares gained 0.03 percent to close at $17.45 on Wednesday.
  • Analysts at BMO Capital downgraded Vitae Pharmaceuticals Inc (NASDAQ: VTAE) from Outperform to Market Perform. Vitae Pharmaceuticals shares declined 0.24 percent to $20.80 in pre-market trading.
  • Goldman Sachs downgraded Atara Biotherapeutics Inc (NASDAQ: ATRA) from Neutral to Sell. The price target for Atara Biotherapeutics has been lowered from $23 to $16. Atara Biotherapeutics shares rose 1.81 percent to close at $21.33 on Wednesday.
  • Barclays downgraded Arch Capital Group Ltd. (NASDAQ: ACGL) from Overweight to Equal-weight. Arch Capital shares fell 0.53 percent to $80.22 in pre-market trading.

Latest Ratings for CTSH

DateFirmActionFromTo
Nov 2017Pivotal ResearchInitiates Coverage OnBuy
Nov 2017BernsteinMaintainsOutperform
Nov 2017Credit SuisseMaintainsOutperform

View More Analyst Ratings for CTSH
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ACGL + AMCX)

View Comments and Join the Discussion!